Burning Rock Biotech Ltd (nasdaq:BNR) Share Price

Company Profile

Business description
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Contact
No. 5, Xingdao Ring Road North
International Bio Island
Guangzhou510005
CHN
T: +86 2034037871
https://www.brbiotech.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
674

Recommended

SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.

Franco Granda | 11 March 2026

Fiercer competition expected to squeeze margins.

Shane Ponraj, CFA | 11 March 2026

This ASX share is 84% overvalued and lacks a sustainable competitive advantage.

Shaun Ler | 10 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,976.80	20.70	0.23%
CAC 40	7,968.20	25.29	-0.32%
DAX 40	23,576.94	391.69	-1.63%
Dow JONES (US)	47,706.51	34.29	-0.07%
FTSE 100	10,311.94	100.30	-0.96%
HKSE	25,898.76	61.14	-0.24%
NASDAQ	22,697.10	1.16	0.01%
Nikkei 225	55,025.37	776.98	1.43%
NZX 50 Index	13,293.13	198.76	1.52%
S&P 500	6,781.48	14.51	-0.21%
S&P/ASX 200	8,743.50	19.40	0.22%
SSE Composite Index	4,133.43	10.29	0.25%